FEB 04, 2019 06:45 PM PST

Eyes Hold the Secret to Islets

WRITTEN BY: Nicholas Breehl

It is said that the eyes are the window to the soul, but they may also open the door for discovering new ways to achieve immune tolerance to transplanted islets in type 1 diabetes, according to research from the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine.

The findings, which were published online on January 31st in Diabetologia, the journal of the European Association for the Study of Diabetes (EASD), show that islets transplanted in the eye can survive and function long-term without continuous immunosuppression, and, moreover, that initial islet transplants within sight of the recipient may lead to long-term peripheral immune tolerance in other transplant sites. The study was conducted in experimental and preclinical (non-human) models of diabetes.

In type 1 diabetes (T1D), the insulin-producing islets cells of the pancreas have been mistakenly destroyed by the immune system, requiring patients to manage their blood sugar levels through a daily regimen of insulin therapy. Islet transplantation has restored natural insulin production in people with type 1 diabetes, as DRI scientists have published. However, patients who receive islet transplants require life-long immunosuppression to prevent rejection of the donor cells. Not only does extended use of anti-rejection drugs pose serious side effects, but the immune attack against the transplanted islets can still occur despite the use of these agents. DRI scientists have been investigating ways to reduce or eliminate the need for anti-rejection therapy, one of the significant research challenges which stands in the way of a biological cure for T1D.

Using a previously established approach that they pioneered, Midhat Abdulreda, Ph.D., DRI assistant professor of surgery, and Per-Olof Berggren, Ph.D., Mary Lou Held Visiting Scientist and adjunct professor of surgery at the DRI, and director of the Rolf Luft Research Center for Diabetes and Endocrinology at the Karolinska Institutet in Stockholm, Sweden, transplanted islets within the anterior chamber of the eye of the experimental and preclinical recipients. Another group received islets implanted in the kidney. Both groups were transiently treated with anti-CD154/CD40L blocking antibody around the transplant period. The antibody prevents the interaction between individual molecules (CD40-CD40L) on the surface of immune system cells that play a crucial role in transplant rejection. DRI researchers have been focused explicitly on this immune pathway because it is particularly promising for islet transplantation.

After performing the initial transplants and administering the antibody treatment, the team then went on to transplant additional islets within the kidney of the experimental group of recipients to evaluate any potential effect on immune tolerance in a site elsewhere in the body.

In both recipient groups -- those receiving an initial islet transplant in either the eye or the kidney along with the short-term treatment with the anti-CD154 antibody -- results showed immunosuppression-free islet survival for more than 300 days. Notably, of the group that initially received islet transplants in the eye, more than 70 percent exhibited survival of the second islet transplant in the kidney for more than 400 days without continued immunosuppression, compared to 30 percent of the recipients that initially received islets in their kidney. Additional studies in the preclinical model showed reduced donor-specific immune reactivity in the blood, consistent with induced peripheral immune tolerance.

"The preliminary findings in these study models of diabetes demonstrate the establishment of immune tolerance towards transplanted islets and their long-term protection from immune attack long after stopping anti-rejection therapy. Further testing in human subjects is needed to validate this approach for people living with type 1 diabetes," said Dr. Abdulreda.

"This approach may help to positively impact the success of islet transplantation for future treatment of diabetes," according to Dr. Berggren.

Sources: Science Daily, Springer, YouTube

About the Author
You May Also Like
JAN 23, 2020
Cell & Molecular Biology
JAN 23, 2020
Understanding and Treating the Mechanisms That Drive Rheumatoid Arthritis
In RA, cells of the immune system mistakenly attack the joints, and cause the painful inflammation that is a hallmark of the disease....
JAN 23, 2020
Immunology
JAN 23, 2020
A Food Additive Could Make Your Cat Hypoallergenic
With 10-30% of the population reporting sensitivity to cat dander, you probably know someone with a cat allergy.  That's why scientists at Nestl&e...
JAN 23, 2020
Immunology
JAN 23, 2020
A New Way To Fight Severe Peanut Allergies
Dr. Sandra Lin explains how SLIT is currently being used to treat allergies other than peanuts.    Over 1 million U.S. children have an allergy t...
JAN 23, 2020
Infographics
JAN 23, 2020
Surface Plasmon Resonance (SPR) Technology
Surface plasmon resonance (SPR) allows researchers to investigate different types of biomolecular interactions and mechanisms in real-time and label-free....
JAN 23, 2020
Genetics & Genomics
JAN 23, 2020
Humans Are Continuing to Evolve, Along With Immune-Related Diseases
Humans have evolved in some ways to be less susceptible to pathogens, but those benefits can also carry risks of other diseases....
JAN 23, 2020
Cell & Molecular Biology
JAN 23, 2020
In a First, Scientists Generate Early Human Immune Cells in the Lab
Now we know more about the early stages of the human immune system....
Loading Comments...